🔗 Share this article The Global Health Body Sounds Concern Over Critical Lack of Weight-Loss Medications Less than a tenth of people who could benefit from obesity jabs such as Wegovy have access to them, caution the global health agency as it publishes its inaugural advice on the medications. Considering in excess of 1,000,000,000 individuals worldwide now obese, it is urging increased and just availability to GLP-1 medication. Per estimates, over two billion could be obese by 2030 if no action is taken. "The new guidance acknowledges that obesity is a chronic disease that can be managed with holistic and ongoing support," remarked its chief Tedros Adhanom Ghebreyesus. High costs, constrained manufacturing, and supply-chain constraints are major obstacles to universal availability to the jabs that can help people shift substantial weight, says the organization. GLP-1 Therapy Scarcity Even in the present best projected case, the production of GLP-1 therapies might only reach around 100 million people – under 10% of eligible patients, per the health organization. The advice calls on countries and companies to widen availability, by measures such as licensing agreements. A patent on a key compound – the primary ingredient of a leading brand – is due to expire in several countries in 2026. The Way Obesity Jabs Function These medications replicate a natural hormone to reduce digestion speed, suppress the appetite and enhance the sense of being full so individuals reduce food intake. Patients typically see weight reduction within a few weeks of beginning the weekly injections. Research indicates patients may see weight return after a year of stopping the treatment, because their normal appetite return. To be above a healthy weight increases your likelihood for developing health problems, like type 2 diabetes, heart disease, stroke, and some malignancies. Excess weight impacts people in all nations and was associated with millions of fatalities worldwide in 2024, as per the health agency.
Less than a tenth of people who could benefit from obesity jabs such as Wegovy have access to them, caution the global health agency as it publishes its inaugural advice on the medications. Considering in excess of 1,000,000,000 individuals worldwide now obese, it is urging increased and just availability to GLP-1 medication. Per estimates, over two billion could be obese by 2030 if no action is taken. "The new guidance acknowledges that obesity is a chronic disease that can be managed with holistic and ongoing support," remarked its chief Tedros Adhanom Ghebreyesus. High costs, constrained manufacturing, and supply-chain constraints are major obstacles to universal availability to the jabs that can help people shift substantial weight, says the organization. GLP-1 Therapy Scarcity Even in the present best projected case, the production of GLP-1 therapies might only reach around 100 million people – under 10% of eligible patients, per the health organization. The advice calls on countries and companies to widen availability, by measures such as licensing agreements. A patent on a key compound – the primary ingredient of a leading brand – is due to expire in several countries in 2026. The Way Obesity Jabs Function These medications replicate a natural hormone to reduce digestion speed, suppress the appetite and enhance the sense of being full so individuals reduce food intake. Patients typically see weight reduction within a few weeks of beginning the weekly injections. Research indicates patients may see weight return after a year of stopping the treatment, because their normal appetite return. To be above a healthy weight increases your likelihood for developing health problems, like type 2 diabetes, heart disease, stroke, and some malignancies. Excess weight impacts people in all nations and was associated with millions of fatalities worldwide in 2024, as per the health agency.